Chris Gibson is a biotechnology executive and scientist who serves as the co founder and chief executive officer of Recursion Pharmaceuticals. He helped establish the company in 2013 to apply machine learning, automation, and large scale biological data analysis to drug discovery. Recursion develops technologies that combine high throughput experimentation with artificial intelligence to identify potential treatments for rare diseases and other conditions. Under Gibson’s leadership, the company has built a platform that generates large biological datasets and uses computational models to map relationships between genes, diseases, and potential therapies. He previously trained as a scientist and has been involved in advancing the use of computational biology and data driven approaches in pharmaceutical research.